The results obtained with GLP-1 supplementation and DPP-4 inhibition in models of endotoxemia are quite promising, but they remind us of the enthusiasm about statins as a new treatment strategy in sepsis and their failure in large clinical trials [270]. The gene discussed is GLP1R; the disease is Sepsis.